Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1

3 Jan 2020

Abstract excerpt

Expansion of an unstable CTG repeat in the 3'UTR of the DMPK gene causes Myotonic Dystrophy type 1 (DM1). CUG-expanded DMPK transcripts (CUGexp) sequester Muscleblind-like (MBNL) alternative splicing regulators in ribonuclear inclusions (foci), leading to abnormalities in RNA processing and splicing. To alleviate the burden of CUGexp, we tested therapeutic approach utilizing antisense oligonucleotides...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Genetic Neurodegenerative Diseases
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31965181
DOI: 10.1093/nar/gkaa007

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1PMID 31965181Read ↗

Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy.Semantic proximity Read ↗

Co-opting MBNL-dependent alternative splicing cassette exons to control gene therapy in myotonic dystrophySemantic proximity Read ↗

Myotonic dystrophy: is a narrow focus obscuring the rest of the field?Semantic proximity Read ↗

Small Molecules Which Improve Pathogenesis of Myotonic Dystrophy Type 1Semantic proximity Read ↗

[Myotonic dystrophy: therapeutic approaches to RNA toxicity].Semantic proximity Read ↗

Antisense oligonucleotides: rising stars in eliminating RNA toxicity in myotonic dystrophy.Semantic proximity Read ↗

Perspectives on gene therapy in myotonic dystrophy type 1.Semantic proximity Read ↗

A Toxic RNA Catalyzes the Cellular Synthesis of Its Own Inhibitor, Shunting It to Endogenous Decay PathwaysSemantic proximity Read ↗

Treating Myotonic Dystrophy with artificial RNA endonucleases to specifically degrade toxic RNA expansionsSemantic proximity Read ↗

Treatment of Type 1 Myotonic Dystrophy by Engineering Site-specific RNA Endonucleases that Target (CUG)n RepeatsSemantic proximity Read ↗

Furamidine Rescues Myotonic Dystrophy Type I Associated Mis-Splicing through Multiple MechanismsSemantic proximity Read ↗

Targeting nuclear RNA for in vivo correction of myotonic dystrophy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.